Han Wei, Cao Fang, Ding Wei, Gao Xiao-Jiao, Chen Fang, Hu Yong-Wei, Ding Hou-Zhong
Department of General Surgery, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu 215300, P.R. China.
Department of Ultrasound, Kunshan First People's Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu 215300, P.R. China.
Oncol Lett. 2018 Feb;15(2):1429-1434. doi: 10.3892/ol.2017.7511. Epub 2017 Dec 5.
Secreted protein acidic and rich in cysteine-like 1 (SPARCL1), a member of extracelluar matrix glycoprotein, has been reported to be associated with various tumor types. The present study aimed to evaluate the prognostic value of SPARCL1 in patients with colorectal cancer. Tissue microarray blocks were constructed based on 79 patients who underwent radical surgery at the Kunshan First People's Hospital between 2008 and 2010. Thirty pairs of fresh-frozen tissues were also obtained for total protein extraction. The expression of SPARCL1 protein was analyzed using immunohistochemistry and western blotting analyses, and the association between overexpressed SPARCL1 and clinicopathological factors was evaluated. Survival analysis with Kaplan Meier curves and Cox regression analysis was used to analyze the prognostic value of SPARCL1. According to western blot analyses, SPARCL1 protein expression in colorectal tumors was significantly lower compared with corresponding normal tissues. The expression of SPARCL1 was markedly decreased from differentiation I to III, and the negative rate of SPARCL1 was higher at Duke's stage C compared with B. Though without any difference between 'positive' and 'negative' in overall survival, significantly higher survival in patients with positive SPARCL1 expression at Duke's stage B was detected in the present study. These results indicated that SPARCL1 may be a potential tumor suppressor gene and associated with good prognosis.
分泌型富含半胱氨酸的酸性蛋白样1（SPARCL1）是细胞外基质糖蛋白家族成员，据报道与多种肿瘤类型相关。本研究旨在评估SPARCL1在结直肠癌患者中的预后价值。基于2008年至2010年期间在昆山市第一人民医院接受根治性手术的79例患者构建组织芯片。还获取了30对新鲜冷冻组织用于总蛋白提取。采用免疫组织化学和蛋白质印迹分析方法分析SPARCL1蛋白的表达情况，并评估SPARCL1过表达与临床病理因素之间的相关性。采用Kaplan-Meier曲线生存分析和Cox回归分析来分析SPARCL1的预后价值。根据蛋白质印迹分析结果，结直肠癌组织中SPARCL1蛋白表达与相应正常组织相比显著降低。从分化I级到III级，SPARCL1的表达明显降低，与B期相比，C期SPARCL1的阴性率更高。虽然总体生存率在“阳性”和“阴性”之间没有差异，但本研究发现B期SPARCL1表达阳性的患者生存率显著更高。这些结果表明，SPARCL1可能是一种潜在的抑癌基因，与良好的预后相关。
